Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Dec 1;16(1):312.
doi: 10.1186/s12920-023-01743-0.

Novel intragenic deletion within the FXN gene in a patient with typical phenotype of Friedreich ataxia: may be more prevalent than we think?

Affiliations
Case Reports

Novel intragenic deletion within the FXN gene in a patient with typical phenotype of Friedreich ataxia: may be more prevalent than we think?

Cinthia Aguilera et al. BMC Med Genomics. .

Abstract

Background: Friedreich ataxia is the most common inherited ataxia in Europe and is mainly caused by biallelic pathogenic expansions of the GAA trinucleotide repeat in intron 1 of the FXN gene that lead to a decrease in frataxin protein levels. Rarely, affected individuals carry either a large intragenic deletion or whole-gene deletion of FXN on one allele and a full-penetrance expanded GAA repeat on the other allele.

Case presentation: We report here a patient that presented the typical clinical features of FRDA and genetic analysis of FXN intron 1 led to the assumption that the patient carried the common biallelic expansion. Subsequently, parental sample testing led to the identification of a novel intragenic deletion involving the 5'UTR upstream region and exons 1 and 2 of the FXN gene by MLPA.

Conclusions: With this case, we want to raise awareness about the potentially higher prevalence of intragenic deletions and underline the essential role of parental sample testing in providing accurate genetic counselling.

Keywords: Biallelic expansion; Deletion; FXN; Friedreich ataxia (FRDA); Parental testing.

PubMed Disclaimer

Conflict of interest statement

Laura Rausell, Pablo Gargallo and Javier Garcia-Planells are employees of Health in Code S.L. All authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Pedigree and genetic analysis of the FXN polymorphic region performed on the proband and his family. The results of PCR fragment analysis show an allele of 7 GAA repeats in the father’s sample (II-3) and an allele of 9 GAA repeats in the mother’s sample (II-4). The sibling (III-1) presents two normal alleles of 7 and 9 GAA repeats, respectively. No peaks were observed in the proband’s sample (III-2). To detect expanded alleles, TP-PCR was performed and, as a result, the father (II-3) and the proband’s (III-2) samples showed an expansion while non-expanded alleles were observed in the mother’s sample (II-4). The affected individuals are marked in black
Fig. 2
Fig. 2
Deletion/duplication analysis of FXN gene and summary of intragenic deletions reported to date. (A) MLPA analysis with the kit P316-B4 showed a deletion of FXN exons 1 and 2 in the mother (II-4) and the proband’s (III-2) samples. The deleted probes are highlighted in red. (B) Summary of FXN gene deletions in the literature and this report

References

    1. Buesch K, Zhang R. POSB355 Health-Related Quality of Life in Friedreich Ataxia: a systematic literature review. Value Heal. 2022;25:229. doi: 10.1016/j.jval.2021.11.1122. - DOI
    1. Bidichandani SI, Delatycki MB, Friedreich Ataxia. GeneReviews®. 2017. https://www.ncbi.nlm.nih.gov/books/NBK1281/. Accessed 16 Oct 2022.
    1. Parkinson MH, Boesch S, Nachbauer W, Mariotti C, Giunti P. Clinical features of Friedreich’s ataxia: classical and atypical phenotypes. J Neurochem. 2013;126 Suppl:103–17. doi: 10.1111/jnc.12317. - DOI - PubMed
    1. Corben LA, Lynch D, Pandolfo M, Schulz JB, Delatycki MB. Consensus clinical management guidelines for Friedreich ataxia. Orphanet J Rare Dis. 2014;9:184. doi: 10.1186/s13023-014-0184-7. - DOI - PMC - PubMed
    1. Anzovino A, Lane DJR, Huang ML-H, Richardson DR. Fixing frataxin: ironing out the metabolic defect in Friedreich’s ataxia. Br J Pharmacol. 2014;171:2174–90. doi: 10.1111/bph.12470. - DOI - PMC - PubMed

Publication types